James Nolan
@jamesnolan.bsky.social
Lymphoma+Cellular Therapies fellow at Princess Margaret Cancer Centre Toronto 🇨🇦/ Physician Scientist in Lymphoma/Chromatin Biology 🇮🇪
Reposted by James Nolan
1/ It's long been assumed that AEBP2 recruit PRC2 to chromatin. Now, we show that AEBP2 usually does the exact opposite:
The only isoform of AEBP2 that is expressed in most cell types and tissues inhibits the chromatin-binding activity of PRC2. www.embopress.org/doi/full/10....
The only isoform of AEBP2 that is expressed in most cell types and tissues inhibits the chromatin-binding activity of PRC2. www.embopress.org/doi/full/10....
Auto-inhibition of PRC2 by the broadly expressed long isoform of AEBP2 | The EMBO Journal
imageimageAEBP2 is an accessory subunit of the PRC2 complex previously implicated both in promoting
and antagonizing Polycomb repressive activity. This study reveals that its alternative
isoforms, AEB...
www.embopress.org
October 31, 2025 at 10:42 PM
1/ It's long been assumed that AEBP2 recruit PRC2 to chromatin. Now, we show that AEBP2 usually does the exact opposite:
The only isoform of AEBP2 that is expressed in most cell types and tissues inhibits the chromatin-binding activity of PRC2. www.embopress.org/doi/full/10....
The only isoform of AEBP2 that is expressed in most cell types and tissues inhibits the chromatin-binding activity of PRC2. www.embopress.org/doi/full/10....
Reposted by James Nolan
1/ 🚀 AEBP2 isn’t what we thought.
You were told that AEBP2 promotes PRC2 activity on chromatin.
We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity.
👉 surl.li/cgwqcq
A thread 🧵
You were told that AEBP2 promotes PRC2 activity on chromatin.
We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity.
👉 surl.li/cgwqcq
A thread 🧵
October 31, 2025 at 10:53 AM
1/ 🚀 AEBP2 isn’t what we thought.
You were told that AEBP2 promotes PRC2 activity on chromatin.
We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity.
👉 surl.li/cgwqcq
A thread 🧵
You were told that AEBP2 promotes PRC2 activity on chromatin.
We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity.
👉 surl.li/cgwqcq
A thread 🧵
Reposted by James Nolan
Very happy to see our paper published online natcomms.nature.com. Thank you to @wellcometrust.bsky.social for funding this work during my time with @robklose.bsky.social and David Booth! Thanks also to collaborators @garcialabms.bsky.social @alexdemendoza.bsky.social and the other authors!
Chromatin profiling identifies putative dual roles for H3K27me3 in regulating cell type-specific genes and transposable elements in choanoflagellates
Nature Communications - Here, the authors investigate chromatin-based gene regulation in the closest relative of animal, choanoflagellates. They uncover a putative dual role for the histone...
rdcu.be
October 29, 2025 at 1:40 PM
Very happy to see our paper published online natcomms.nature.com. Thank you to @wellcometrust.bsky.social for funding this work during my time with @robklose.bsky.social and David Booth! Thanks also to collaborators @garcialabms.bsky.social @alexdemendoza.bsky.social and the other authors!
Pleased to present at #ESMO25 the 16 year experience of tandem high-dose chemotherapy and autologous stem cell transplant for relapsed/refractory advanced stage germ cell tumours from Princess Margaret Cancer Centre, Toronto 🇨🇦
October 18, 2025 at 11:13 AM
Pleased to present at #ESMO25 the 16 year experience of tandem high-dose chemotherapy and autologous stem cell transplant for relapsed/refractory advanced stage germ cell tumours from Princess Margaret Cancer Centre, Toronto 🇨🇦
🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on www.biorxiv.org/content/10.1.... Here's a thread summarizing our findings!👇
#CancerResearch #Epigenetics #Chromatin #Lymphoma
#CancerResearch #Epigenetics #Chromatin #Lymphoma
AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma
The catalytic subunit of Polycomb Repressive Complex 2 (PRC2), EZH2, is recurrently mutated in 25% of diffuse large B-cell lymphomas (DLBCL), causing increased H3K27me3 and decreased H3K27me2 levels. ...
www.biorxiv.org
October 17, 2025 at 7:11 AM
🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on www.biorxiv.org/content/10.1.... Here's a thread summarizing our findings!👇
#CancerResearch #Epigenetics #Chromatin #Lymphoma
#CancerResearch #Epigenetics #Chromatin #Lymphoma
Reposted by James Nolan
Excited to share our new paper out today in @cp-molcell.bsky.social! We show that the H3K27M oncohistone rewires cPRC1, creating a unique dependency on CBX4/PCGF4-containing complexes, and also reveal a previously unknown function of CBX4. Highlights below (1/11).
May 21, 2025 at 4:13 PM
Excited to share our new paper out today in @cp-molcell.bsky.social! We show that the H3K27M oncohistone rewires cPRC1, creating a unique dependency on CBX4/PCGF4-containing complexes, and also reveal a previously unknown function of CBX4. Highlights below (1/11).
Reposted by James Nolan
Our work identifying CBX4 as a potential therapeutic target for diffuse midline glioma has just been published in Molecular Cell! Check out co-first author @eimearlagan.bsky.social’s overview below.
Excited to share our new paper out today in @cp-molcell.bsky.social! We show that the H3K27M oncohistone rewires cPRC1, creating a unique dependency on CBX4/PCGF4-containing complexes, and also reveal a previously unknown function of CBX4. Highlights below (1/11).
May 21, 2025 at 9:25 PM
Our work identifying CBX4 as a potential therapeutic target for diffuse midline glioma has just been published in Molecular Cell! Check out co-first author @eimearlagan.bsky.social’s overview below.
Reposted by James Nolan
🧵 1/ We’re excited to share that our new paper with @adrianbracken.bsky.social lab is out 🎉 In this study (which began over 10 years ago!), we explore the biology of PRC2 and PRC1 in non-dividing cells. We also explore the effects of PRC2 inhibitor drugs on these cells. Here’s what we found👇
January 14, 2025 at 10:57 PM
🧵 1/ We’re excited to share that our new paper with @adrianbracken.bsky.social lab is out 🎉 In this study (which began over 10 years ago!), we explore the biology of PRC2 and PRC1 in non-dividing cells. We also explore the effects of PRC2 inhibitor drugs on these cells. Here’s what we found👇
Reposted by James Nolan
Congrats to @jamesnolan.bsky.social (now at @pmresearch-uhn.bsky.social) on his #ASH24 abstract achievement award for his PhD research @tcddublin.bsky.social! @adrianbracken.bsky.social 🇮🇪🇨🇦 @ash-hematology.bsky.social #Lmsm #ASHKudos
December 10, 2024 at 5:49 PM
Congrats to @jamesnolan.bsky.social (now at @pmresearch-uhn.bsky.social) on his #ASH24 abstract achievement award for his PhD research @tcddublin.bsky.social! @adrianbracken.bsky.social 🇮🇪🇨🇦 @ash-hematology.bsky.social #Lmsm #ASHKudos
Looking forward to sharing collaborative work by myself and @dr-chromatin.bsky.social from the labs of @adrianbracken.bsky.social and @conwayer1.bsky.social at #ASH24 in San Diego this week. #hemesky #lymsm please feel free to stop by and share your thoughts.
December 5, 2024 at 7:04 PM
Looking forward to sharing collaborative work by myself and @dr-chromatin.bsky.social from the labs of @adrianbracken.bsky.social and @conwayer1.bsky.social at #ASH24 in San Diego this week. #hemesky #lymsm please feel free to stop by and share your thoughts.
Reposted by James Nolan
🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼
PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼
A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼
doi.org/10.1182/bloo...
#MedSky #HemeSky
PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼
A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼
doi.org/10.1182/bloo...
#MedSky #HemeSky
November 21, 2024 at 4:38 PM
🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼
PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼
A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼
doi.org/10.1182/bloo...
#MedSky #HemeSky
PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼
A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼
doi.org/10.1182/bloo...
#MedSky #HemeSky
Reposted by James Nolan
How does PRC1 counteract transcription?
See this preview from @adrianbracken.bsky.social and I on an exciting new study from @robklose.bsky.social lab where they show ncPRC1 blocks the early stages of transcription.
www.sciencedirect.com/science/arti...
@conwayer1.bsky.social for title inspo!
See this preview from @adrianbracken.bsky.social and I on an exciting new study from @robklose.bsky.social lab where they show ncPRC1 blocks the early stages of transcription.
www.sciencedirect.com/science/arti...
@conwayer1.bsky.social for title inspo!
ScienceDirect.com | Science, health and medical journals, full text articles and books.
authors.elsevier.com
November 20, 2024 at 11:19 PM
How does PRC1 counteract transcription?
See this preview from @adrianbracken.bsky.social and I on an exciting new study from @robklose.bsky.social lab where they show ncPRC1 blocks the early stages of transcription.
www.sciencedirect.com/science/arti...
@conwayer1.bsky.social for title inspo!
See this preview from @adrianbracken.bsky.social and I on an exciting new study from @robklose.bsky.social lab where they show ncPRC1 blocks the early stages of transcription.
www.sciencedirect.com/science/arti...
@conwayer1.bsky.social for title inspo!
Reposted by James Nolan
My colleague @fergutierrezro1 giving an excellent talk at #ESHBMFS2024 on the clinical implications of clonal hematopoiesis in #telomere biology disorders 🧬; dependent on specific mutation with U2AF1, TP53, and chr1+ associated with #MDSsm and #AMLsm.
November 16, 2024 at 1:28 PM
My colleague @fergutierrezro1 giving an excellent talk at #ESHBMFS2024 on the clinical implications of clonal hematopoiesis in #telomere biology disorders 🧬; dependent on specific mutation with U2AF1, TP53, and chr1+ associated with #MDSsm and #AMLsm.